-
Something wrong with this record ?
Active surveillance study of adverse events following immunisation of children in the Czech Republic
J. Danova, A. Kocourkova, AM. Celko,
Language English Country England, Great Britain
Document type Journal Article
NLK
BioMedCentral
from 2001-12-01
BioMedCentral Open Access
from 2001
Directory of Open Access Journals
from 2001
Free Medical Journals
from 2001
PubMed Central
from 2001
Europe PubMed Central
from 2001
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2001-01-01
Medline Complete (EBSCOhost)
from 2001-01-01
Health & Medicine (ProQuest)
from 2009-01-01
Public Health Database (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
Springer Nature OA/Free Journals
from 2001-12-01
- MeSH
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Population Surveillance MeSH
- Adverse Drug Reaction Reporting Systems statistics & numerical data MeSH
- Vaccination adverse effects MeSH
- Age Factors MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
BACKGROUND: Despite the undisputed public health benefits of routine vaccination, adverse events following immunisation (AEFI) remain a concern. As most adverse events are mild, they may be under-reported; this may underlie the wide range of AEFI rates reported in the literature. We investigated the rates of AEFI related to routine vaccination of children 0-10 years old in the Czech Republic. METHODS: The study reviewed patients' records in a sample of 49 paediatric GP practices covering all 12 administrative regions of the Czech Republic between 2011 and 2013. Adverse events following routine immunisation of children aged 0-10 years were identified and recorded. RESULTS: The overall rate of AEFI was 209/100,000 doses; this was 6 times higher than the rate reported to the Czech State Institute for Drug Control (34/100,000 doses). Over two fifths (44%) of all AEFI occurred after the booster dose of the combined diphteria, tetanus and pertussis vaccine in 5-year old children. The vast majority of AEFI were non-serious local events (e.g. redness) and fever. Most AEFI occurred the second day after the immunisation, lasted 4 days on average, and were treated by cold therapy, antipyretics and analgesics. CONCLUSIONS: The rate of AEFI identified in this study was considerably higher than the officially reported rate. Although the vast majority of AEFI were non-serious, health care providers and the public should be educated and encouraged to report AEFI to address the issue of underreporting, to increase the safety profile of vaccines, and to improve public confidence in immunisation programmes.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031064
- 003
- CZ-PrNML
- 005
- 20171025115422.0
- 007
- ta
- 008
- 171025s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12889-017-4083-4 $2 doi
- 035 __
- $a (PubMed)28166783
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Danova, Jana $u Department of Epidemiology, Third Faculty of Medicine Charles University, Prague, Czech Republic. jana.danova@lf3.cuni.cz.
- 245 10
- $a Active surveillance study of adverse events following immunisation of children in the Czech Republic / $c J. Danova, A. Kocourkova, AM. Celko,
- 520 9_
- $a BACKGROUND: Despite the undisputed public health benefits of routine vaccination, adverse events following immunisation (AEFI) remain a concern. As most adverse events are mild, they may be under-reported; this may underlie the wide range of AEFI rates reported in the literature. We investigated the rates of AEFI related to routine vaccination of children 0-10 years old in the Czech Republic. METHODS: The study reviewed patients' records in a sample of 49 paediatric GP practices covering all 12 administrative regions of the Czech Republic between 2011 and 2013. Adverse events following routine immunisation of children aged 0-10 years were identified and recorded. RESULTS: The overall rate of AEFI was 209/100,000 doses; this was 6 times higher than the rate reported to the Czech State Institute for Drug Control (34/100,000 doses). Over two fifths (44%) of all AEFI occurred after the booster dose of the combined diphteria, tetanus and pertussis vaccine in 5-year old children. The vast majority of AEFI were non-serious local events (e.g. redness) and fever. Most AEFI occurred the second day after the immunisation, lasted 4 days on average, and were treated by cold therapy, antipyretics and analgesics. CONCLUSIONS: The rate of AEFI identified in this study was considerably higher than the officially reported rate. Although the vast majority of AEFI were non-serious, health care providers and the public should be educated and encouraged to report AEFI to address the issue of underreporting, to increase the safety profile of vaccines, and to improve public confidence in immunisation programmes.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a systémy pro sběr zpráv o nežádoucích účincích léků $x statistika a číselné údaje $7 D016907
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a Česká republika $7 D018153
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a surveillance populace $7 D011159
- 650 _2
- $a vakcinace $x škodlivé účinky $7 D014611
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kocourkova, Aneta $u Department of Epidemiology, Third Faculty of Medicine Charles University, Prague, Czech Republic.
- 700 1_
- $a Celko, Alexander M $u Department of Epidemiology, Third Faculty of Medicine Charles University, Prague, Czech Republic.
- 773 0_
- $w MED00008205 $t BMC public health $x 1471-2458 $g Roč. 17, č. 1 (2017), s. 167
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28166783 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171025115505 $b ABA008
- 999 __
- $a ok $b bmc $g 1254657 $s 992091
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 17 $c 1 $d 167 $e 20170206 $i 1471-2458 $m BMC public health $n BMC Public Health $x MED00008205
- LZP __
- $a Pubmed-20171025